1 – 10 of 10
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)
(
- Contribution to journal › Article
- 2023
-
Mark
Management of antineutrophil cytoplasmic antibody–associated vasculitis with glomerulonephritis as proposed by the ACR 2021, EULAR 2022 and KDIGO 2021 guidelines/recommendations
(
- Contribution to journal › Scientific review
-
Mark
Traditional and Disease-Specific Risk Factors for Cardiovascular Events in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis : A Multinational Retrospective Study
(
- Contribution to journal › Article
- 2022
-
Mark
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS
(
- Contribution to journal › Scientific review
- 2021
-
Mark
COVID-19 and ANCA-associated vasculitis : Recommendations for vaccine preparedness and the use of rituximab
(
- Contribution to journal › Letter
-
Mark
Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis : A multinational study
(
- Contribution to journal › Article
- 2019
-
Mark
Renal relapse in antineutrophil cytoplasmic autoantibody-associated vasculitis : unpredictable, but predictive of renal outcome
(
- Contribution to journal › Article
- 2018
-
Mark
Comment on : Rituximab therapy for takayasu arteritis: A seven patients experience and a review of the literature
(
- Contribution to journal › Letter
- 2017
-
Mark
Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis
(
- Contribution to journal › Article
- 2016
-
Mark
Rituximab for treatment of severe renal disease in ANCA associated vasculitis
(
- Contribution to journal › Article